Skip to main content
. Author manuscript; available in PMC: 2014 Sep 16.
Published in final edited form as: Cochrane Database Syst Rev. 2012 Mar 14;3:CD004706. doi: 10.1002/14651858.CD004706.pub4
Outcomes Hazard ratio (95% CI)
Chemotherapy versus observation
No of participants (studies) Quality of the evidence (GRADE) Comments
Overall 5-yr survival HR 0.71 (0.53 to 0.93) 1006 women
(three studies)
⊕⊕⊕⊕
high
Homogeneous data (I2 = 0%); P = 0.01
Overall 10-yr survival HR 0.74 (0.58 to 0.95) 925 women
(two studies)
⊕⊕⊕⊕
high
Homogeneous data (I2 = 0%);. P = 0.02
Progression-free 5-yr survival HR 0.67 (0.53 to 0.84) 1170 women
(four studies)
⊕⊕⊕⊕
high
Homogeneous data (I2 = 0%); P = 0.0005
Progression-free 10-yr survival HR 0.67 (0.54 to 0.84) 925 women
(two studies)
⊕⊕⊕⊕
high
Homogeneous data (I2 = 0%); P = 0.0005
Overall 5-yr survival: sub-optimal staging* HR 0.63 (0.46 to 0.85) 772 women
(two studies)
⊕⊕⊕⊕
high
Homogeneous data (I2 = 0%); P = 0.003
Progression-free 5-yr survival: sub-optimal staging** RR 0.64 (0.50 to 0.82) 934 women
(three studies)
⊕⊕⊕⊕
high
Homogeneous data (I2 = 19%); P = 0.0004
Overall 5-yr survival: optimal staging* HR 1.22 (0.63 to 2.37) 234 women
(two studies)
⊕⊕⊕○
moderate
Quality of the evidence downgraded to ‘moderate’ due to small subgroup size (I2 = 0%; P = 0.56)*
Progression-free 5-yr survival: optimal staging** RR 0.67 (0.36 to 1.22) 234 women
(two studies)
⊕⊕⊕○
moderate
Quality of the evidence downgraded to ‘moderate’ due to small subgroup size (I2 = 0%; P = 0.19)

CI: confidence interval; HR: hazard ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

*

Tests for subgroup differences between optimal and sub-optimal subgroups for the 5-year OS outcome were Chi2 = 3.14, df = 1 (P = 0.08) and I2 = 68.1%. We consider this to be a significant difference.

**

Tests for subgroup differences between optimal and sub-optimal subgroups for the 5-year PFS outcome showed that the subgroups were not different with respect to this outcome (P = 0.91; I2 = 0%).